MAILLY, F and TUGRUL, Y and REYMER, PWA and BRUIN, T and SEED, M and GROENEMEYER, BF and ASPLUNDCARLSON, A and VALLANCE, D and WINDER, AF and MILLER, GJ and KASTELEIN, JJP and HAMSTEN, A and OLIVECRONA, G and HUMPHRIES, SE and TALMUD, PJ (1995) A COMMON VARIANT IN THE GENE FOR LIPOPROTEIN-LIPASE (ASP9-]ASN) - FUNCTIONAL IMPLICATIONS AND PREVALENCE IN NORMAL AND HYPERLIPIDEMIC SUBJECTS. ARTERIOSCL THROM VAS , 15 (4) 468 - 478.
Full text not available from this repository.
Subjects with combined hyperlipidemia (CHL) were screened for mutations in the lipoprotein lipase (LPL) gene by single-strand conformational polymorphism, and a previously reported G-->A DNA sequence change in exon 2, causing substitution of Asp by Asn at position 9, was identified in 2 individuals. Because this substitution destroys a recognition site for Tag I, pooling of DNA samples, amplification, and digest with Tag I allowed the rapid screening of 1563 healthy individuals and patients of Dutch, Swedish, English, and Scottish origin. In the general populations of all four countries, healthy carriers of the mutation were detected at a frequency of 1.6% to 4.4% (mean, 3.0%; 95% confidence interval, 2.0% to 4.0%). The frequency of carriers was roughly twice as high (range, 4.0% to 9.8%) in selected patients with CHL or type IV hyperlipoproteinemia or in subjects with angiographically assessed atherosclerosis; the frequency was consistently higher in each patient group compared with its matched control group. In 773 healthy men from two general practices in the United Kingdom, 25 carriers and 2 homozygotes for the mutation were identified. In these 27, plasma triglyceride but not plasma cholesterol levels were significantly higher than in noncarriers (2.25 versus 1.82 mmol/L, P<.02), and this difference was maintained in three subsequent annual measurements. Postheparin LPL activity data were available for some carriers and for 7 of 9 individuals from the patient groups, and 6 of 6 individuals from the control groups had LPL activity that was lower than the respective group mean. In vitro mutagenesis and transient expression in COS cells showed that compared with the LPL-Asp9 construct, LPL-Asn9 activity and mass were reduced by 20% to 30% in the culture media. Overall however, LPL-Asn9 had only slightly reduced specific activity (by 18%). Thus, although the precise mechanism of the effect is unclear, the data strongly suggest that the LPL-Asn9 variant is associated with and may play a direct role in predisposing carriers to develop hypertriglyceridemia.
|Title:||A COMMON VARIANT IN THE GENE FOR LIPOPROTEIN-LIPASE (ASP9-]ASN) - FUNCTIONAL IMPLICATIONS AND PREVALENCE IN NORMAL AND HYPERLIPIDEMIC SUBJECTS|
|Keywords:||FAMILIAL COMBINED HYPERLIPIDEMIA, GENETIC PREDISPOSITION, LIPOPROTEIN LIPASE, FAMILIAL COMBINED HYPERLIPIDEMIA, CORONARY HEART-DISEASE, MYOCARDIAL-INFARCTION, DNA POLYMORPHISMS, PLASMA, ASSOCIATIONS, TRIGLYCERIDE, EXPRESSION, DEFICIENCY, SURVIVORS|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science|
Archive Staff Only: edit this record